This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since the first implementation in 2002 by Alain Cribier, transcatheter aorticvalve replacement (TAVR) has become a standard procedure for high-risk and elderly patients with severe aorticvalve stenosis. Recently, the use of TAVR has expanded to relatively younger patients with low to moderate surgical risk.
This study aimed to determine if pulse pressure and aorticvalve peak velocity could serve as early predictors of heart failure with preserved ejection fraction in patients with myocardial infarction. to 1.97), and a similar association was observed for aorticvalve peak velocity (HR: 1.37, 95% CI 1.19 m/s had a 2.10-fold
In an era of rapidly expanding use of transcatheter aorticvalve implantation (TAVI), the management of patients with bicuspid aorticvalve (BAV) disease is far less well established than in those with trileaflet anatomy.
Bicuspid aorticvalve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration.
Transcatheter aorticvalve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.
Background Bicuspid aorticvalve (BAV) is the most common congenital heart defect in adults, often leading to complications such as thoracic aortic aneurysms and aortic stenosis. While BAV is frequently associated with 22q11.2 This study is aimed to assess the role of rare 22q11.2 region (18–24 Mb).
Small aortic annulus poses a major challenge in aorticvalve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aorticvalve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aorticvalve replacement.
This Viewpoint advocates for prompt aorticvalve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aortic stenosis.
Studies were excluded if they weren’t exclusively conducted on patients submitted to surgical aorticvalve replacement using the Inspiris Resilia bioprosthesis. Its performance appears to be equal to or better than many other bioprosthetic valves. Results The technical success rate was almost perfect in all studies.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aorticvalve system (Xcor system, Saint Medical Technology, Inc.,
Genetic variants linked to a rare form of bicuspid aorticvalve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications have been identified by researchers at UTHealth Houston.
(MedPage Today) -- LOS ANGELES -- Survival outcomes favored mechanical valves for isolated surgical aorticvalve replacement (SAVR) for people until age 60, after which a tissue valve may start to have an advantage, according to a large registry.
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aorticvalve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aortic stenosis who underwent successful TAVR.
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aorticvalve replacement (TAVR).
milla1cf Tue, 12/12/2023 - 07:00 December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aorticvalve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
This randomized clinical trial evaluates the safety and efficacy of administration of protamine to reduce bleeding following transcatheter aorticvalve implantation vs placebo, selective protamine administration.
Shettys team followed 252 patients who underwent the Ross procedure, a heart valve replacement operation commonly used to treat younger patients with severe aorticvalve disease. Freedom from aortic regurgitation was 95.1%, 92.2%, 87.7%, and 84.5% Shettys team found that survival rates were 95.8% at 5 years, 94.3%
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aorticvalve disease.
What is the relationship between aorticvalve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
(MedPage Today) -- Transcatheter aorticvalve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aorticvalve replacement, according to the EARLY TAVR.
A significant proportion of patients with severe aortic stenosis (AS) undergoing transcatheter aorticvalve implantation (TAVI) have concomitant coronary artery disease (CAD). The best way to treat these patients is contentious.
Bileaflet mechanical heart valves (MHV) remain a viable option for aorticvalve replacement, particularly for younger patients and patients from low- and middle-income countries and underserved communities. Despite their exceptional durability, MHV recipients are at increased risk of thromboembolic complications.
Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Aim This study aimed to systematically review and analyse the existing evidence on outcomes of emergency transcatheter aorticvalve implantation (eTAVI) and emergency balloon aortic valvuloplasty (eBAV) in CS patients.
Objectives The clinical outcomes of transcatheter aorticvalve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
This cohort study examines whether there is an association between osteosarcopenia and adverse outcomes, such as increased risk of mortality, in older adults following transcatheter aorticvalve replacement (TAVR).
Quadricuspid aorticvalve (QAV) is rare. However, to repair a quadricuspid aorticvalve is not as easy to realize as in bicuspid aorticvalve. The surgical design is crucial to rebuild the stable structure.
The co-occurrence of a bicuspid aorticvalve (BAV) with TSC is exceedingly rare.Case summaryWe report the case of a 26-year-old woman with genetically confirmed TSC, harboring a novel pathogenic variant in the TSC2 gene. multi-system characteristics of TSC were also presented, affecting skin, brain, lung, kidney, and bone.
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aorticvalve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aortic stenosis (narrowing of the aorticvalve).
The goal of the AVATAR trial was to evaluate aorticvalve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
In the 22 years since Professor Alain Cribier performed the first transcatheter aorticvalve implantation (TAVI) in Rouen in France, treatment pathways for patients with aorticvalve stenosis have evolved rapidly.
A transthoracic echocardiogram (TTE) revealed a mobile mass on the right coronary cusp of the aorticvalve ( figure 1 , ). cm) at the right coronary cusp of the aorticvalve on the long-axis and short-axis parasternal view. Figure 1 A mobile mass (1.88 Question What is the most likely diagnosis?
Background Closure of paravalvular leak (PVL) regurgitation after self-expandable (SE) transcatheter aorticvalve implantation (TAVI) may be more challenging than after balloon-expandable (BE) valve implantation. MN, USA).
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aorticvalve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heart valve (BHV) leaflet materials.
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content